Advertisement

Search Results

Advertisement



Your search for The A matches 30539 pages

Showing 1 - 50


lung cancer

Perioperative Tislelizumab Plus Chemotherapy in Resectable NSCLC

In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment with the checkpoint inhibitor tislelizumab plus platinum-doublet chemotherapy led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the...

bladder cancer

Final Results of the POUT Trial: Adjuvant Chemotherapy vs Surveillance After Nephroureterectomy for Upper Tract Urothelial Cancer

As reported in the Journal of Clinical Oncology by Alison Jane Birtle, MD, MBBS, MRCP, FRCR, and colleagues, final results of the UK-based phase III POUT trial showed survival benefits with adjuvant platinum-based chemotherapy vs surveillance after radical nephroureterectomy in patients with upper...

breast cancer
genomics/genetics

Genetic Alterations Associated With Interval Breast Cancer Diagnosis

In a Swedish study reported in JAMA Oncology, Rodriguez et al identified characteristics of interval breast cancers—those diagnosed between two screening examinations—compared with screen-detected cancers on the basis of analysis of rare germline genetic deleterious protein-truncating variants. As...

cns cancers

TBI and Risk of Brain Cancer in Veterans of the Iraq and Afghanistan Wars

In a retrospective cohort study reported in JAMA Network Open, Stewart et al found that U.S. veterans of the Iraq and Afghanistan wars with moderate/severe or penetrating traumatic brain injury (TBI) were at an increased risk of brain cancer compared to those without TBI. Study Details The study...

breast cancer
genomics/genetics

Does Risk-Reducing Mastectomy Reduce the Risk of Breast Cancer—and Mortality?

Investigators have found that risk-reducing mastectomy decreases the risk of receiving a breast cancer diagnosis and the likelihood of mortality in female patients with BRCA1 or BRCA2 genetic variants, according to a recent study published by Metcalfe et al in the British Journal of Cancer....

geriatric oncology
issues in oncology

Modified Chemotherapy Regimens May Improve Quality of Life in Older Patients With Advanced Cancer

Reducing doses and adjusting chemotherapy schedules in older patients with advanced cancer may help improve treatment tolerability without compromising its efficacy, according to a recent study published by Mohamed et al in JAMA Network Open. Background Standard chemotherapy regimens—mostly based...

issues in oncology

Analysis of Cancer Diagnoses After Recent Weight Loss

In a study reported in JAMA, Wang et al found that individuals with a weight loss of more than 10% during the prior 2 years had a higher risk of cancer diagnosis over the subsequent 12 months vs those with no weight loss. Study Details The retrospective cohort analysis included women aged at least...

lung cancer

FDA Approves Osimertinib With Chemotherapy for EGFR-Mutated NSCLC

On February 16, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an...

skin cancer
immunotherapy

FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma

On February 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for adult patients with unresectable or metastatic melanoma who were previously treated with a PD-1 blocking antibody, or, if they have...

skin cancer
issues in oncology

Neoadjuvant Chemotherapy May Benefit Patients With Penile Squamous Cell Carcinoma

Researchers have found that neoadjuvant chemotherapy may be safe and effective in patients with locally advanced penile squamous cell carcinoma, according to a recent study published by Rose et al in the Journal of the National Cancer Institute. The findings may help address a critical gap in...

pancreatic cancer
issues in oncology

Ablative Stereotactic Magnetic Resonance–Guided Adaptive Radiation Therapy for Pancreatic Ductal Adenocarcinoma

Researchers have found that ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy may improve local control and overall survival in patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma, according to a recent study published by Chuong et ...

lung cancer

FDA Approves Tepotinib for Metastatic NSCLC

On February 15, the U.S. Food and Drug Administration (FDA) granted traditional approval to the kinase inhibitor tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations. The agent is...

myelodysplastic syndromes

Expert Point of View: David A. Sallman, MD, and Mikkael A. Sekeres, MD

Two experts in myelodysplastic syndromes (MDS) discussed the findings on the combination of venetoclax plus azacitidine in the treatment of higher-risk MDS with The ASCO Post. David A. Sallman, MD, Assistant Member in the Department of Malignant Hematology, Moffit Cancer Center, Tampa, provided...

myelodysplastic syndromes

Venetoclax Plus Azacitidine Evaluated in High-Risk Myelodysplastic Syndromes

For the treatment of high-risk, treatment-naive myelodysplastic syndromes (MDS), the regimen of venetoclax plus azacitidine led to high response rates, durable responses, and encouraging overall survival, in a phase Ib study reported at the 2023 American Society of Hematology (ASH) Annual Meeting...

myelodysplastic syndromes

Expert Point of View: Prithviraj Bose, MD

Prithviraj Bose, MD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, shared his thoughts on MANIFEST-2 and TRANSFORM-1 with The ASCO Post. While both were international phase III trials that showed similar benefits with two different...

myelodysplastic syndromes

First-Line Ruxolitinib Combinations Boost Benefit Over Single Agent in Myelofibrosis

In two international phase III trials in myelofibrosis, drugs given in combination with the Janus kinase (JAK) inhibitor ruxolitinib in JAK inhibitor–naive patients significantly improved outcomes vs ruxolitinib alone. Both studies were presented at the 2023 American Society of Hematology Annual...

lymphoma

Expert Point of View: Dipenkumar Modi, MD

The ASCO Post obtained comments on the Smart Stop study from Dipenkumar Modi, MD, a medical oncologist and hematologist at the Barbara Ann Karmanos Cancer Institute and Assistant Professor of Oncology at Wayne State University School of Medicine, Detroit. Dr. Modi applauded the investigators for...

lymphoma

Study Finds Four-Drug Targeted Treatment Reduces Chemotherapy Requirement for Some in Large B-Cell Lymphoma

A four-drug targeted therapy regimen proved safe and effective as the first-line treatment of diffuse large B-cell lymphoma (DLBCL), achieving a 100% response rate after four cycles, researchers from The University of Texas MD Anderson Cancer Center, Houston, reported at the 2023 American Society...

lymphoma

Expert Point of View: Carla Casulo, MD

Session co-moderator Carla Casulo, MD, offered her thoughts on the response-adapted use of ultra-low–dose radiotherapy in gastric MALT (mucosa-associated lymphoid tissue) lymphoma, as reported by the investigators from MD Anderson Cancer Center. Dr. Casulo is Associate Professor of Medicine and...

lymphoma

‘Ultra-Low Dose’ of Radiotherapy May Be Enough in Gastric MALT Lymphoma, Study Finds

For patients with gastric MALT (mucosa-associated lymphoid tissue) lymphoma, an “ultra-low dose” of radiotherapy was as effective as the higher, standard dose in providing local control and freedom from distant relapse, researchers from The University of Texas MD Anderson Cancer Center reported at...

Steven A. Rosenberg, MD, PhD, Honored With 2024 AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) will award Steven A. Rosenberg, MD, PhD, Fellow of the AACR Academy, with the 2024 AACR Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting, to be held April 5–10 in San Diego. His award lecture will be presented on...

multiple myeloma

Expert Point of View: Cynthia E. Dunbar, MD

In a press briefing at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, Cynthia E. Dunbar, MD, ASH Secretary and Chief of the Translational Stem Cell Biology Branch, Intramural Research Program of the National Heart, Lung, and Blood Institute, offered her thoughts on...

multiple myeloma

Real-World Experience Mirrors PERSEUS Findings

At the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers from Emory University presented a real-world comparison of the largest cohort of patients with newly diagnosed multiple myeloma consecutively treated with either bortezomib, lenalidomide, and dexamethasone ...

leukemia

PEGasparaginase Dosing and Risk of Hypersensitivity Reactions in Pediatric ALL

In a Dutch study reported in the Journal of Clinical Oncology, van der Sluis et al found that continuous dosing of PEGasparaginase was associated with a significantly reduced incidence of hypersensitivity reactions vs standard noncontinuous dosing in newly diagnosed pediatric patients with...

multiple myeloma

Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE

Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...

Highlights From the 2023 ASH Annual Meeting & Exposition

Hordes of classical and malignant hematologists returned to the tranquil city of San Diego for the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition this past December. The packed agenda lit the Gaslight District up with neuron-searing data, creating an environment for...

Expert Point of View: Michael Crump, MD

Michael Crump, MD, of the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, expressed some concerns about the study presented by Shadman et al in patients with large B-cell lymphoma (LBCL). “These data should be interpreted with caution. The patient...

lymphoma

Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission?

For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of...

breast cancer

Adjuvant Olaparib for Germline BRCA1/2-Mutant, High-Risk HER2-Negative Early Breast Cancer: Patient-Reported Outcomes From the OlympiA Trial

In a patient-reported outcomes analysis from the phase III OlympiA trial reported in the Journal of Clinical Oncology, Patricia A. Ganz, MD, FASCO, and colleagues found no clinically important differences in fatigue—the outcome of primary interest—between adjuvant olaparib and placebo in patients...

Expert Point of View: Peter Voorhees, MD

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Durham, North Carolina, introduced the plenary presentation of the phase III IsKia trial by Gay et al and further commented on the study for The ASCO...

multiple myeloma

Addition of Isatuximab to Carfilzomib-Based Regimen Doubles MRD Negativity Rates in Multiple Myeloma

In the phase III IsKia trial in newly diagnosed multiple myeloma, therapy incorporating the CD38-directed monoclonal antibody isatuximab-irfc with a carfilzomib-based regimen led to high rates of minimal residual disease (MRD) negativity at postconsolidation cutoffs, as reported at the 2023...

Expert Point of View: William G. Blum, MD and Mikkael Sekeres, MD, MS

Thoughts on the study by Othman et al were provided by William G. Blum, MD, Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of the Acute Leukemia Program at Winship Cancer Institute, and Mikkael Sekeres, MD, MS, Professor of...

leukemia

In NPM1-Mutated AML, Benefit of Transplant Limited to Patients With Residual Disease

In patients with NPM1-mutated acute myeloid leukemia (AML), the presence of molecular measurable residual disease (MRD) in the peripheral blood following induction chemotherapy can aid decision-making about postremission therapy. More specifically, MRD status in the peripheral blood can identify...

multiple myeloma

Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest

Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...

multiple myeloma

PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma

The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-­eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...

multiple myeloma
immunotherapy

STAb T-Cell–Based Immunotherapy in Multiple Myeloma

A novel immunotherapy based on STAb T cells may be more effective at treating multiple myeloma than chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Díez-Alonso et al in Science Translational Medicine. Background Multiple myeloma is the second most common...

prostate cancer
issues in oncology

Racial Representation Affects Trust for Black Patients Seeking Prostate Cancer Information Online

Among Black patients with prostate cancer, racial representation may be a key factor affecting their trust in websites offering information on the disease, according to a recent study published by Loeb et al in The Journal of Urology. Background Black men may have higher rates of prostate cancer...

breast cancer

Triplet for Advanced HER2-Negative Breast Cancer

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research published by Roussos Torres et al in Nature Cancer. The regimen included a histone deacetylase (HDAC) inhibitor combined with two types of checkpoint...

palliative care

Understanding the Discordance About Prognosis Between Clinicians and Terminally Ill Patients and Their Surrogates

Research shows that about half of adults near the end of life in the United States are too ill to participate in decisions about whether to accept life-prolonging treatment,1 requiring family members and other proxies to serve as surrogate decision-makers for their critically ill loved ones....

pancreatic cancer

System to Improve Clinical Staging in Localized Pancreatic Cancer

In a Trans-Atlantic Pancreatic Surgery Consortium study reported in the Journal of Clinical Oncology, Dekker et al found that the “ABC” clinical staging system could be used to differentiate overall survival outcomes in patients with localized pancreatic ductal adenocarcinoma. Study Details The...

lung cancer
immunotherapy

Durvalumab Plus Ceralasertib in Patients With Immunotherapy-Resistant NSCLC

The combination of the anti–PD-L1 antibody durvalumab and the ATR kinase inhibitor ceralasertib may help overcome inherent immune resistance and reinvigorate antitumor activity in patients with advanced non–small cell lung cancer (NSCLC), according to a recent study published by Besse et al in...

sarcoma
immunotherapy

Neoadjuvant Immunotherapy May Improve Long-Term Survival in Patients With Resectable Soft-Tissue Sarcoma

Patients with soft-tissue sarcoma treated with neoadjuvant immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to phase II trial results published by Roland et al in Nature Cancer. Background About 13,000 new cases of soft-tissue...

breast cancer

Molecular Subtype–Based Therapy in the First-Line Treatment of Metastatic or Recurrent Triple-Negative Breast Cancer

In a Chinese single-institution phase II trial (FUTURE-SUPER) reported in The Lancet Oncology, Fan et al found that molecular subtype–based therapy produced promising results in the first-line treatment of metastatic or recurrent triple-negative breast cancer.  Study Details In the open-label...

pancreatic cancer

FDA Approves Irinotecan Liposome for the First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

On February 13, the U.S. Food and Drug Administration (FDA) approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma. NAPOLI-3 Efficacy was evaluated in NAPOLI-3 (ClinicalTrials.gov identifier...

skin cancer

MIA Calculator for Predicting Recurrence-Free and Overall Survival in Stage II Melanoma

In a study reported in the Journal of Clinical Oncology, Varey et al developed the Melanoma Institute Australia (MIA) calculator for predicting recurrence-free and overall survival in stage II melanoma and found that it outperformed modeling based on American Joint Committee on Cancer (AJCC)-8th...

breast cancer

Postmenopausal Patients With ER-Rich/HER2-Negative Breast Cancer: Neoadjuvant Therapies

In a phase III trial reported in JAMA Oncology, Cynthia X. Ma, MD, PhD, and colleagues found that neither neoadjuvant fulvestrant nor anastrozole plus fulvestrant improved the endocrine-sensitive disease (ESD) rate vs anastrozole alone among postmenopausal patients with phase II to III estrogen...

prostate cancer
symptom management
supportive care

Plant-Based Diet May Be Linked to Improved Sexual Health in Men Treated for Prostate Cancer

Plant-based diets may be linked to a lower risk of erectile dysfunction, urinary incontinence, and other common side effects experienced by patients receiving treatment for prostate cancer, according to a new study published by Loeb et al in Cancer. The findings indicated that nutrition may lead to ...

cardio-oncology

Sleep Apnea May Be Prevalent Among Patients With Cancer at High Risk of Congestive Heart Failure

Sleep apnea may be prevalent among patients who are at higher risk of developing congestive heart failure from cancer therapy, according to new findings presented by Das et al at the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient course. Background...

gynecologic cancers

Trabectedin vs Chemotherapy in Recurrent Ovarian Cancer With BRCA Mutation or BRCAness Phenotype

As reported in the Journal of Clinical Oncology by Domenica Lorusso, MD, PhD, and colleagues, the Italian phase III MITO-23 trial showed no overall survival benefit with trabectedin vs chemotherapy in women with recurrent ovarian cancer with a BRCA mutation or BRCAness phenotype. Study Details In ...

leukemia

Crenolanib and Intensive Chemotherapy in Newly Diagnosed FLT3-Mutated AML

In a pilot study reported in the Journal of Clinical Oncology, Eunice S. Wang, MD, and colleagues found that the combination of crenolanib and intensive chemotherapy produced high response rates in adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Crenolanib is a...

Advertisement

Advertisement




Advertisement